Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07844551 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To evaluate the efficacy and safety of Becotatug Vedotin (EGFR-targeted ADC, MRG003) plus Pucotenlimab (PD-1 inhibitor), compared with platinum-based chemotherapy/chemoradiotherapy, as an induction conversion regimen for downstaging primary stage IVB oral squamous cell carcinoma or HPV16-negative oropharyngeal squamous cell carcinoma.
Trial Details
NCT Number NCT07844551
Lead Sponsor Huashan Hospital
Conditions
(from sponsor)		 Stage IVB Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Related terms Carcinoma, Squamous Cell Carcinoma of Head and Neck
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov